Key clinical point: Adding 2 years of ovarian function suppression to standard tamoxifen therapy could improve disease-free and overall survival in previously treated women with estrogen receptor–positive breast cancer.

Major finding: The 5-year estimated disease-free survival rate was 91.1% for patients who received tamoxifen and OFS, compared with 87.5% for those who received tamoxifen alone.

Study details: A phase 3, randomized trial involving 1,293 premenopausal women with estrogen receptor–positive breast cancer who were previously treated with chemotherapy and definitive surgery.

Disclosures: The study was primarily funded by AstraZeneca with additional support from the Korea Institute of Radiological and Medical Sciences. The investigators disclosed relationships with Novartis, Roche, Amgen, and others.